Pas-004 Capsules
RAF Mutation
Pasithea Therapeutics Corp.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the RAF Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tovorafenib Day One Biopharmaceuticals, Inc. | Phase 2 | CC |
Dcc-3084 Deciphera Pharmaceuticals, LLC | Phase 1 | CC |
Pas-004 Tablets Pasithea Therapeutics Corp. | Phase 1 | CC |
Abm-168 ABM Therapeutics Corporation | Phase 1 | CC |
msc1936369b Day One Biopharmaceuticals, Inc. | Phase 1 | CC |
Same molecule, other indications
Pas-004 Capsules is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →